PTC Therapeutics, Inc.
Substituted reverse pyrimidine Bmi-1 inhibitors
Last updated:
Abstract:
Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
Status:
Grant
Type:
Utility
Filling date:
26 Sep 2019
Issue date:
23 Nov 2021